retatrutide weight loss phase 2 trial results Experimental drug shows promising in Triumph-1 Trial Results for Retatrutide

The patch uses SMGT (Sustained Micro-Gradient Technology) to deliver GLP-1 through a network of painless microneedles that gently penetrate the upper layer of the skin

Standard prescription access requires FDA approval, projected for late 2027 to 2028

Research programmes exploring energy expenditure mechanisms, hepatic lipid metabolism, or multi-receptor metabolic modelling require a triple-axis compound that tirzepatide cannot provide

Paradoxically, rapidly improving blood sugar can worsen diabetic retinopathy in susceptible individuals, especially those with longstanding, poorly controlled diabetes and high baseline A1c

As part of this voluntary model, CMS will negotiate drug pricing and coverage terms with GLP-1 manufacturers on behalf of state Medicaid programs and Medicare Part D plan sponsors

Phase 2 trial data showed no MACE signal but were not powered to detect cardiovascular outcomes